Failed trial puts Shield shares on the rollercoaster
This article was originally published in Clinica
Executive Summary
Shield Diagnostics' test for the blood clotting protein, activated factor XII (AFT), is a better predictor of heart disease than measurements of lipid levels or fibrinogen, according to preliminary data from the multicentre Northwick Park study. However, the company has been rocked by news that AFT data from the much larger US ARIC study of cardiovascular is useless. Shield's shares had climbed to an all time high of 790 pence earlier this month but tumbled back to around 620 pence on news that blood samples stored for use in the 16,000-patient ARIC study had clotted during storage, rendering them useless. Shares closed up at 690 pence on news of the Northwick Park data on March 23rd.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.